Lead Product(s) : ISD017
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : US patent covering the lead candidate ISD017, which uniquely blocks all aspects of STING pathway overactivation in severe systemic lupus erythematosus (SLE) patients.
Product Name : ISD017
Product Type : Peptide
Upfront Cash : Inapplicable
May 26, 2021
Lead Product(s) : ISD017
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Tavotek Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions, using DuoBody® technology, proprietary platform of Genmab A/S of Denmark.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
May 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Tavotek Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement